Trial Profile
Phase II Pilot Study of Subsequent Line Gemcitabine and Nivolumab for Advanced SCLC
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Nivolumab (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 31 Jan 2021 Status changed from to discontinued, according to Results presented at the 2020 World Conference on Lung Cancer
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 15 Oct 2020 Planned End Date changed from 10 Sep 2021 to 1 Aug 2022.